Liraglutide reduces risk of cardiovascular death (LEADER results)

First published June 2016, updated March 2022   The GLP-1 receptor analogue liraglutide (Victoza) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% versus placebo, in addition to standard of care in 9,340 adults with type 2 diabetes at high CV risk. The main results of the LEADER trial were presented at the American Diabetes Association’s 76th Scientific Sessions (ADA) and also published in the New England Journal of Medicine. Liraglutide is the only approved GLP-1 receptor agonist to demonstrate a superior reduction of major CV